JP2016512214A5 - - Google Patents

Download PDF

Info

Publication number
JP2016512214A5
JP2016512214A5 JP2015562176A JP2015562176A JP2016512214A5 JP 2016512214 A5 JP2016512214 A5 JP 2016512214A5 JP 2015562176 A JP2015562176 A JP 2015562176A JP 2015562176 A JP2015562176 A JP 2015562176A JP 2016512214 A5 JP2016512214 A5 JP 2016512214A5
Authority
JP
Japan
Prior art keywords
bispecific antibody
epitope
amino acid
tfpi
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015562176A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016512214A (ja
JP6586016B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2014/055055 external-priority patent/WO2014140240A1/en
Publication of JP2016512214A publication Critical patent/JP2016512214A/ja
Publication of JP2016512214A5 publication Critical patent/JP2016512214A5/ja
Application granted granted Critical
Publication of JP6586016B2 publication Critical patent/JP6586016B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015562176A 2013-03-15 2014-03-14 組織因子系凝固インヒビター上の２つのエピトープに特異的に結合することが可能な抗体 Active JP6586016B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361789274P 2013-03-15 2013-03-15
EP13159515 2013-03-15
EP13159515.9 2013-03-15
US61/789,274 2013-03-15
PCT/EP2014/055055 WO2014140240A1 (en) 2013-03-15 2014-03-14 Antibodies capable of specifically binding two epitopes on tissue factor pathway inhibitor

Publications (3)

Publication Number Publication Date
JP2016512214A JP2016512214A (ja) 2016-04-25
JP2016512214A5 true JP2016512214A5 (https=) 2017-04-20
JP6586016B2 JP6586016B2 (ja) 2019-10-02

Family

ID=47877935

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015562176A Active JP6586016B2 (ja) 2013-03-15 2014-03-14 組織因子系凝固インヒビター上の２つのエピトープに特異的に結合することが可能な抗体

Country Status (6)

Country Link
US (2) US9896513B2 (https=)
EP (1) EP2970499B1 (https=)
JP (1) JP6586016B2 (https=)
CN (1) CN105209497B (https=)
ES (1) ES2926773T3 (https=)
WO (1) WO2014140240A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010072691A1 (en) 2008-12-22 2010-07-01 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
EP3022228B1 (en) * 2013-07-19 2019-02-27 Novo Nordisk A/S Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
SG10201804945WA (en) * 2013-12-12 2018-07-30 Shanghai hengrui pharmaceutical co ltd Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof
FI3277321T3 (fi) 2015-04-01 2024-10-31 Anaptysbio Inc T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita
KR102438650B1 (ko) 2015-08-19 2022-08-31 화이자 인코포레이티드 조직 인자 경로 억제제 항체 및 그의 용도
CN106554420A (zh) * 2015-09-30 2017-04-05 上海众合医药科技股份有限公司 Pcsk9抗体、其抗原结合片段及其医药用途
EP3388838B1 (en) * 2016-01-29 2022-02-16 Sony Group Corporation Blood coagulation analysis
MX2019005116A (es) * 2016-11-01 2019-11-12 Anaptysbio Inc Anticuerpos dirigidos contra la proteina de inmunoglobulina de linfocitos t y de mucina 3 (tim-3).
WO2018129553A1 (en) 2017-01-09 2018-07-12 Tesaro, Inc. Methods of treating cancer with anti-tim-3 antibodies
CA3115607A1 (en) 2018-10-11 2020-04-16 Pfizer Inc. Dosage regimen for tfpi antagonists
WO2020097338A1 (en) * 2018-11-07 2020-05-14 Baudax Bio, Inc. Methods of treating subjects having platelet dysfunction with iv meloxicam
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
CN112390884B (zh) * 2019-04-09 2022-07-08 苏州大学 Semaphorin7A单克隆抗体及其在制备用于治疗炎症疾病药物方面的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
ES2136595T5 (es) 1989-04-19 2004-04-01 Enzon, Inc. Carbonatos activos de oxidos de polialquileno para la modificacion de polipeptidos.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0539975A1 (en) * 1991-10-31 1993-05-05 Teijin Limited Method for immunological assay of free lipoprotein-associated coagulation inhibitor (LACI) and kit therefor
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
EP0979102A4 (en) 1997-04-30 2005-11-23 Enzon Inc DETAILED POLYPEPTIDE MODIFIED BY POLYALKYLENE OXIDE
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
ES2411007T3 (es) 2001-10-10 2013-07-04 Novo Nordisk A/S Remodelación y glicoconjugación de péptidos
PL1615945T3 (pl) 2003-04-09 2012-03-30 Ratiopharm Gmbh Sposoby glikopegylacji i białka/peptydy wytwarzane tymi sposobami
WO2005040219A1 (en) 2003-10-28 2005-05-06 Novo Nordisk A/S Laminin-5 gamma2-binding peptides, related compositions, and use thereof
MX2007015676A (es) 2005-06-15 2008-02-20 Novo Nordisk Healthcare Ag Conjugacion de la hormona de crecimiento mediada por transglutaminasa.
WO2010072691A1 (en) 2008-12-22 2010-07-01 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
EP2379599B1 (en) 2008-12-22 2015-09-02 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor (tfpi)
JP2013533871A (ja) 2010-06-30 2013-08-29 ノヴォ ノルディスク アー／エス 組織因子経路インヒビターに特異的に結合することが可能な抗体
PL2694544T3 (pl) 2011-04-01 2019-07-31 Bayer Healthcare Llc Przeciwciała monoklonalne przeciwko inhibitorowi szlaku czynnika tkankowego (TFPI)

Similar Documents

Publication Publication Date Title
JP2016512214A5 (https=)
HRP20240719T1 (hr) Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba
AR075798A1 (es) Proteinas de union a il-17 (interleuquina 17)
HRP20220811T1 (hr) Agonistička sredstva za vezanje tnf receptora
JP2017529097A5 (https=)
EA201991099A1 (ru) Антитела против cd73 и их применение
HRP20150439T1 (hr) Protutijela za humani angiopoietin 2
WO2017152102A3 (en) Anti-trem1 antibodies and methods of use thereof
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
IL259940B2 (en) Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
EA032189B9 (ru) Изолированные человеческие моноклональные антитела против ингибитора пути тканевого фактора (tfpi) и фармацевтическая композиция, содержащая их
PE20181363A1 (es) Variantes optimizadas de anticuerpos anti-vegf
JP2017113019A5 (https=)
HRP20161656T4 (hr) Sredstva za vezanje na cd33
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
PE20171180A1 (es) Anticuerpos anti-pd-1 y sus metodos de uso
JP2017518258A5 (https=)
AR065506A1 (es) Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades
RU2015136078A (ru) Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний
EA201201227A1 (ru) Бипаратопные а-бета-связывающие полипептиды
JP2017508475A5 (https=)
WO2017060322A3 (en) Ptefb-inhibitor-adc
JP2017512825A5 (https=)
JP2017529870A5 (https=)
JP2020502198A5 (https=)